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Abstract
Background: Although tissue microarrays (TMAs) are commonly employed in clinical and basic-science research, there 
are no guidelines for evaluating the appropriateness of a TMA for a given biomarker and tumor type. Furthermore, TMA 
performance across multiple biomarkers has not been systematically explored.
Methods: A simulated TMA with between 1 and 10 cores was designed to study tumor expression of 6 biomarkers 
with varied expression patterns (B7-H1, B7-H3, survivin, Ki-67, CAIX, and IMP3) using 100 patients with clear cell renal 
cell carcinoma (RCC). We evaluated agreement between whole tissue section and TMA immunohistochemical 
biomarker quantification to assess how many TMA cores are necessary to adequately represent RCC whole tissue 
section expression. Additionally, we evaluated associations of whole tissue section and TMA expression with RCC-
specific death.
Results: The number of simulated TMA cores necessary to adequately represent whole tissue section quantification is 
biomarker specific. Although 2-3 cores appeared adequate for B7-H3, Ki-67, CAIX, and IMP3, even as many as 10 cores 
resulted in poor agreement for B7-H1 and survivin compared to RCC whole tissue sections. While whole tissue section 
B7-H1 was significantly associated with RCC-specific death, no significant associations were detected using as many as 
10 TMA cores, suggesting that TMAs can result in false-negative findings if the TMA is not optimally designed.
Conclusions: Prior to TMA analysis, the number of TMA cores necessary to accurately represent biomarker expression 
on whole tissue sections should be established as there is not a one-size-fits-all TMA. We illustrate the use of a 
simulated TMA as a cost-effective tool for this purpose.
Background
Over the last decade, tissue microarrays (TMAs) have
become a commonly-used research tool to evaluate asso-
ciations between biomarkers and clinicopathologic tumor
features, patient outcomes and treatment responses. In
fact, TMAs are routinely prepared by lead national can-
cer cooperative groups (e.g., RTOG, SWOG, ECOG, etc.)
with the expectation of revealing or testing various bio-
markers for prognostication of disease outcome or
response to therapy. The appeal of TMAs has been their
ability to interrogate hundreds of tissue specimens using
a uniform experimental process, while simultaneously
preserving limited tissue resources. Although TMAs are
convenient and relatively inexpensive, eagerness to
exploit this technology has outpaced a comprehensive
understanding of its capabilities and limitations. There is
no standardized approach to TMA creation, usage or
interpretation, particularly for use with multiple bio-
markers.
TMAs were initially developed as a high-throughput
tool to validate results obtained from gene-expression
microarrays [1]. Gene-expression microarray studies are
typically performed using only a small number of speci-
mens and thus the identified biomarkers must be vali-
dated on hundreds of specimens to evaluate the
diagnostic or prognostic value of the candidate bio-
marker. Even though TMAs were developed to aid this
validation process by evaluating hundreds of specimens
in a high-throughput manner, Kononen et al. [1] recog-
nized the limitations of sampling only fractions of whole
tissue specimens and acknowledged that the results from
TMAs may need to be verified by analyzing larger tissue
specimens before clinical application.
One of the most recognized limitations of this technol-
ogy is that the small cores used to construct a TMA may
not accurately represent characteristics of the whole tis-
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sue specimen [2,3]. To construct a TMA, representative
areas from paraffin-embedded, formalin-fixed tumor tis-
sue blocks are selected, cores 0.6-2.0 mm in diameter are
punched from the blocks, and the punched samples are
subsequently arrayed into a recipient block (referred to as
a TMA; see Figure 1 in Giltnane and Rimm 2004 for an
in-depth description). Anywhere from 2-4 cores taken
from the center, randomly, or peripherally from one or
more formalin-fixed tumor tissue blocks are used to cre-
ate a TMA. Thus, the total area of tumor represented by a
TMA can differ by more than 20-fold, ranging from 0.565
to 12.57 mm2.
Although it is frequently reported that a TMA has been
validated, use of this term is variable. The claim that a
TMA has been validated often denotes that the TMA was
previously used to find an association between a single
biomarker and a single clinicopathologic feature. Details
pertaining to how the TMA was validated - for instance,
how well the biomarker was represented by the TMA
compared to whole tissue sections - are sometimes not
published, not well described, or are limited in their
interpretation by insufficient sample sizes. There is also a
tendency to assume that a TMA can be used to study
multiple biomarkers within the same cancer without a
thorough understanding of the potentially disparate
expression patterns of these biomarkers.
To better understand the consequences of tumor het-
erogeneity on TMA performance, numerous investiga-
tions have compared agreement between TMA and
whole tissue section quantification. Based on these stud-
ies, a general consensus is that 3-to-4 cores are sufficient
to adequately represent whole tissue specimens [4-7].
Camp et al. [8] suggested that 2 cores provide valuable
and accurate results, preferably 1 from the tumor edge
and 1 from the tumor center. Unfortunately, most studies
pertaining to TMA performance have been limited in
both size and scope, and have not thoroughly addressed
the fundamental issue as to whether a limited number of
TMA cores are sufficient across a variety of biomarkers.
Herein, we demonstrate that the design of a TMA is
biomarker-specific and that, in fact, a TMA may not be
an appropriate tool for some biomarkers. Specifically, the
objectives of this study were: (i) to evaluate the agreement
between whole tissue section quantification and TMA
quantification to assess how many TMA cores are neces-
sary to adequately represent whole tissue section expres-
sion for biomarkers with different expression patterns, (ii)
to evaluate the suitability of TMAs to identify known
associations between biomarker expression and RCC-
specific death across biomarkers with different expres-
sion patterns, and (iii) to establish the use of a simulated
TMA as a cost-effective tool for evaluating the effective-
ness of a TMA for a particular study or tumor type. To do
so, we simulate the creation of a TMA with as few as 1
and as many as 10 cores to study tumor expression of B7-
H1, B7-H3, survivin, Ki-67, CAIX, and IMP3 in clear cell
renal cell carcinoma (ccRCC). Although a comparison of
TMA and whole tissue sections has been done for sur-
vivin [9,10], Ki-67 [11-13], and CAIX [14,15] these com-
parisons have not been conducted using ccRCC tumors.
Furthermore, comparisons of TMA quantification with
whole tissue sections for B7-H1, B7-H3 and IMP3 are
lacking altogether.
Figure 1 Simulated TMA template mask. (A) 19 equally spaced 0.6 mm viewing ports and the TMA template placed below the objective of a mi-
croscope, and (B) the order of the 10 cores used for quantification of tumor biomarker expression.
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Methods
Patient Selection and Outcome
Using the Mayo Clinic Nephrectomy Registry, 100
patients were randomly selected from 351 who were
treated with radical or partial nephrectomy for unilateral,
sporadic, non-cystic ccRCC between 1995 and 1999. Vital
status for patients in the Mayo Clinic Nephrectomy Reg-
istry is updated each year. If a patient has died in the pre-
vious year, a death certificate is ordered to determine the
cause of death. A recent visit to Mayo (within 6 months of
the date of death) for metastatic disease is good docu-
mentation that RCC was the cause of death. If the death
certificate does not support this, the medical history is
reviewed by a Mayo urologist to determine the cause of
death. If a death certificate cannot be obtained, the cause
of death must be verified with the patient's family or local
physician.
Immunohistochemical Staining and Quantification
Sections from paraffin-embedded tissue blocks were
immunohistochemically stained for B7-H1, B7-H3, sur-
vivin, Ki-67, CAIX, and IMP3 as previously described
[16-21]. The membranous and cytoplasmic staining pat-
terns of B7-H1, B7-H3, CAIX, and IMP3 were quantified
as the percentage of positive tumor cells in 5-10% incre-
ments, whereas the nuclear staining patterns of survivin
and KI-67 were quantified as the number of positive
tumor cells per mm2. Quantification for the original
whole tissue sections was conducted by a single patholo-
gist (Y.S.) between August and December of 2006. To
provide a measure of intra-reader variability, the study
pathologist repeated the whole tissue section quantifica-
tion for all six biomarkers, blinded to the original whole
tissue section quantification. The repeated whole tissue
section quantification for the 100 patients was conducted
approximately one year after the initial review, between
November of 2007 and January of 2008.
Simulated TMA Construction and Quantification
A simulated TMA was constructed using a stainless steel
template mask with dimensions 31 × 20 × 0.15 mm. A Yag
laser was used to bore 19 equally-spaced 0.6 mm viewing
ports (from core center to core center) in a circular pat-
tern spanning 5 mm in diameter (Figure 1A). The result-
ing TMA template was thin enough to be placed on a
glass slide below the objective of a microscope, yet sturdy
enough to be used repeatedly on hundreds of slides. Of
the 19 cores on the simulated TMA, only 10 were utilized
for manual quantification; the 10 cores were selected to
provide representative assessments of both the center of
the tumor tissue and the surrounding edges (Figure 1B).
The whole tissue sections that were previously stained
for B7-H1, B7-H3, survivin, KI-67, CAIX, and IMP3 were
collected and the patient information on each slide was
replaced with study identifiers ranging from 1 to 100 for
each biomarker. To blind the pathologist, only the techni-
cians and statisticians had access to the link between the
patient information and the identifiers. For TMA quanti-
fication, the pathologist first viewed each slide under low
magnification to determine the center of the tumor tis-
sue, without regard to the immunohistochemical staining
pattern. The center of the TMA template was then placed
on the area of the slide that contained the center of the
tumor tissue. Subsequently, tumor biomarker expression
was quantified for the 10 labeled cores on the TMA tem-
plate for each slide (Figure 1B). For cores that contained
at least 25% tumor tissue, the membranous and cytoplas-
mic staining patterns of B7-H1, B7-H3, CAIX, and IMP3
were quantified as the percentage of positive tumor cells
in 5-10% increments, whereas the nuclear staining pat-
terns of survivin and KI-67 were quantified as the num-
ber of positive tumor cells per mm2. Cores that contained
primarily normal, stromal, artifact, necrotic, or degenera-
tive tissue and cores that did not contain any tissue at all
were recorded as such.
Statistical Methods
The goals of this study were: (i) to evaluate the agreement
between whole tissue section quantification and TMA
quantification to assess how many TMA cores are neces-
sary to adequately represent whole tissue section expres-
sion for biomarkers with different expression patterns,
and (ii) to evaluate the suitability of TMAs to identify
known associations between biomarker expression and
RCC-specific death across biomarkers with different
expression patterns.
To evaluate the agreement between whole tissue sec-
tion quantification and TMA quantification, the agree-
ment between repeated whole tissue section
quantification (i.e., whole tissue section intra-reader
agreement) was first evaluated as a point of reference.
Note that the first and second whole tissue section quan-
tifications were performed approximately one year apart.
Whole tissue section intra-reader agreement was mea-
sured using the kappa statistic [22] and the concordance
correlation coefficient (CCC) [23]. The kappa statistic is
designed for categorical data and is a measure of the dif-
ference between the observed agreement and the amount
of agreement that would be expected by chance. Kappa
statistics of 0.01-0.20, 0.21-0.40, 0.41-0.60, 0.61-0.80, and
0.81-0.99 represent slight, fair, moderate, substantial, and
almost perfect agreement, respectively. The CCC is
designed for continuous data and measures the variation
from the 45-degree line through the origin (the concor-
dance line); values range from 0.0 to 1.0, with higher val-
ues indicating a greater level of agreement [23].
Since the kappa statistics and CCCs indicated that the
whole tissue section intra-reader agreement was good, weEckel-Passow et al. Diagnostic Pathology 2010, 5:48
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compared the simulated TMA quantification with the
second whole tissue section quantification. The goal was
to evaluate how many cores (from 1 and up to 10) are
needed to achieve adequate agreement in biomarker
expression between the simulated TMA and the whole
tissue section. Bootstrap resampling was performed to
simulate varying numbers of cores. For each bootstrap
sample, the simulated number of cores (from 1 and up to
10) was randomly sampled from each patient without
replacement and the expression values across the corre-
sponding informative cores for each patient were summa-
rized by the maximum expression value for B7-H1, B7-
H3, survivin, KI-67, and IMP3 and by the minimum
expression value for CAIX. Note that higher expressions
of B7-H1, B7-H3, survivin, KI-67, and IMP3 are associ-
ated with RCC-specific death, whereas lower expression
of CAIX is associated with RCC-specific death [16-21].
The bootstrap procedure was executed 500 times for
each simulated number of cores. Agreement between the
summarized TMA quantification and the second whole
tissue section quantification was evaluated for all patients
with at least one informative core using the kappa statis-
tic and the CCC. The TMA template was designed to
simulate the creation of TMAs with as few as 1 and as
many as 10 cores, some of which could be non-informa-
tive due to heterogeneity in tumor tissue or the process-
ing of the TMA template. As such, the bootstrap
resampling procedure could choose a non-informative
core, which in fact mimics a real TMA.
To evaluate associations of whole tissue section and
TMA biomarker expression with RCC-specific death,
bootstrap resampling was used to evaluate associations of
biomarker expression with RCC-specific death using 1
and up to 10 cores [7]. For each bootstrap sample, the
simulated number of cores (from 1 and up to 10) was ran-
domly sampled from each patient without replacement
and the expression values across the corresponding cores
for each patient were summarized by the maximum
expression value for B7-H1, B7-H3, survivin, KI-67, and
IMP3 and by the minimum expression value for CAIX.
The bootstrap procedure was executed 500 times for
each simulated number of cores. Cox proportional haz-
ards regression was used to evaluate the association
between biomarker expression and RCC-specific death
via the Wald chi-square statistic. The duration of follow-
up was calculated from the date of surgery to the date of
death or last follow-up as of February 2008. Patients who
died from causes other than RCC were censored at the
date of death; patients who were still alive at the time of
analysis were censored at the date of last follow-up.
Results and Discussion
The clinicopathologic features for the 100 randomly
selected patients are described in Table 1. Patients were
mostly male (67%), ECOG 0 (77%), pNX/pN0 (96%), M0
(96%), and TNM stage group I (56%). These clinicopatho-
logic features are representative of the available 351
ccRCC patients from our 1995 to 1999 cohort (data not
shown). At last follow-up, 50 of the 100 patients had died,
including 24 who died from RCC at a median of 1.6 years
following surgery (range 0.2 - 10.5). Among the 50
patients who were still alive, the median duration of fol-
low-up was 9.1 years (range 2.3 - 13.0).
Table 1: Clinicopathologic features for 100 patients treated 
surgically for ccRCC between 1995 and 1999
Feature N
Gender
Female 33
Male 67
Symptomatic at Presentation 51
ECOG Performance Status
07 7
12 1
22
2002 Primary Tumor Classification
pT1a 25
pT1b 32
pT2 18
pT3a 10
pT3b 13
pT3c 0
pT4 2
Regional Lymph Node Involvement
pNX/pN0 96
pN1/pN2 4
Distant Metastases
M0 96
M1 4
2002 TNM Stage Groupings
I5 6
II 16
III 21
IV 7
Nuclear Grade
12
25 7
33 3
48
Coagulative Tumor Necrosis 21
Sarcomatoid Differentiation 4Eckel-Passow et al. Diagnostic Pathology 2010, 5:48
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A summary of the whole tissue section quantification
for each biomarker is provided in Table 2. B7-H1 expres-
sion was nearly dichotomous for the 100 ccRCC tumors
studied; there were 92, 7, and 1 tumor with 0%, 5%, and
10% B7-H1 expression, respectively. As such, B7-H1
expression was analyzed as positive (i.e., 5% or greater)
versus negative. Before evaluating the agreement in bio-
marker expression between whole tissue section quantifi-
cation and TMA quantification, we first evaluated whole
tissue section intra-reader agreement. The two whole tis-
sue section readings were conducted by a single patholo-
gist approximately one year apart. The kappa statistic for
B7-H1 was 0.78, signifying substantial agreement
between the repeated whole tissue section quantifica-
tions. The CCCs for survivin, Ki-67, CAIX, IMP3, and
B7-H3 were 0.71, 0.90, 0.94, 0.96, and 0.97, respectively
(T able 3). As shown in Additional file 1, Figure S1, the
intra-reader agreement for survivin and Ki-67 was a func-
tion of expression since the magnitude of disagreement
increased as expression increased.
Allowing the whole tissue section intra-reader agree-
ment to serve as a point of reference, we evaluated the
agreement in biomarker expression between the second
whole tissue section quantification and the quantification
using a simulated TMA. Table 3 provides measures of
agreement between the summarized TMA and the sec-
ond whole tissue section quantifications. The minimum,
median, and maximum agreement measure (kappa or
CCC) from the 500 bootstrap simulations is provided for
each biomarker. Using only 2 cores, the median kappa
statistic for B7-H1 was 0.21 and the median CCCs for
survivin, Ki-67, IMP3, B7-H3, and CAIX were 0.40, 0.72,
0.79, 0.81, and 0.82, respectively. The results for 3 cores
were very similar to those of 2 cores. Although 2-to-3
cores might be adequate for Ki-67, IMP3, B7-H3, and
CAIX (CCC > 0.70), more than 3 cores are clearly neces-
sary for B7-H1 and survivin. As such, we observed that
the number of cores necessary for a TMA to adequately
represent whole tissue section quantification is clearly
not the same for all biomarkers. Even when using all 10
cores, the agreement between the TMA and whole tissue
section was noticeably worse than the intra-reader agree-
ment between repeated quantifications of the whole tis-
sue section.
Significant associations between B7-H1, B7-H3, sur-
vivin, Ki-67, IMP3, and CAIX with RCC-specific death
have been reported in the literature using whole tissue
section quantification [16-21] and thus our goal was to
determine if a TMA could corroborate these associations.
For the Cox analysis, B7-H1 was modeled as dichoto-
mous (positive versus negative), whereas the remaining
biomarkers were modeled as continuous. Table 4 pro-
vides a summary of associations of the second whole tis-
sue section quantification with RCC-specific death.
Figure 2 illustrates the distribution of Wald chi-square
statistics from 500 bootstrap samples testing associations
of biomarker expression with RCC-specific death using 1
and up to 10 cores from the simulated TMA. Using a sig-
nificance level of 0.05, the critical value for a 1 degree-of-
freedom chi-square test statistic is approximately 3.8. For
B7-H3 (Figure 2A), the median chi-square statistic
remained stable from 1 to 10 cores; however, the variabil-
ity associated with the statistics (i.e., the width of the
boxes) decreased dramatically from 1 to 2 cores. For sur-
vivin, Ki-67, CAIX, and IMP3 (Figures 2B-E) the median
chi-square statistic became stable after 4 to 5 cores. Fur-
thermore, the 25th  percentile of chi-square values
increased as the number of cores increased, suggesting
that the association between expression and RCC-spe-
cific death was strengthened by using more cores. Even
though the associations between CAIX and RCC-specific
death (Figure 2D) were strengthened by using more
cores, most of the chi-square statistics were less than 3.84
and thus the associations were non-significant regardless
Table 2: Summary of biomarker expression for the second whole tissue section quantification
Distribution of expression values
Biomarker
Quantitation
Method*
0%
(min) 10% 25%
50%
(median) 75% 90%
100%
(max)
B7-H1 % 0 0 0 0 0 0 10
B7-H3 % 0 0 0 0 0 5 100
IMP3 % 0 0 0 0 0 10 80
CAIX % 0 20 100 100 100 100 100
Survivin mm2 0.65 1.95 2.61 4.56 12.38 25.41 82.08
Ki-67 mm2 0.65 2.61 12.05 24.76 41.69 68.08 329.64
*The membranous and cytoplasmic staining patterns of B7-H1, B7-H3, IMP3, and CAIX were quantitated as the percentage of positive tumor 
cells in 5-10% increments, whereas the nuclear staining patterns of survivin and KI-67 were quantitated as the number of positive tumor cells 
per mm2.Eckel-Passow et al. Diagnostic Pathology 2010, 5:48
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of the number of cores studied. This result is not surpris-
ing since the association of CAIX with RCC-specific
death using whole tissue sections was also non-signifi-
cant (Table 4), suggesting that our study of 100 patients
lacks statistical power to detect associations of CAIX
expression with outcome. Lastly, although use of whole
tissue sections showed a significant association of B7-H1
expression with RCC-specific death (Table 4), most of the
chi-square statistics from the simulated TMA were less
than 3.84 (Figure 2F), regardless of the number of cores
studied. Therefore, B7-H1 is an example of a focal and
rarely expressed biomarker that is not well suited for
TMA analysis when evaluating the association of expres-
sion with RCC-specific death.
Conclusions
While it is frequently reported in the literature that a
TMA has been previously validated, details pertaining to
this validation are often absent or are not well described.
In many instances, the observed association of TMA bio-
marker expression with a single clinicopathologic feature
of the cancer of interest is provided as evidence that the
TMA has been validated and TMA technology can there-
fore be used to study other biomarkers in the same cancer
or the same biomarker in other cancers. As such, prior to
preparing a TMA, the number of TMA cores necessary
to accurately represent whole tissue section biomarker
expression should be established on a biomarker-specific
and cancer-specific basis. We established the use of a
simulated TMA as a cost-effective tool for this purpose.
The first objective of this study was to evaluate agree-
ment between whole tissue section quantification and
quantification using a simulated TMA to determine the
number of TMA cores necessary to adequately represent
whole tissue section expression for 6 biomarkers that
ha ve been shown to be associated with ccRCC patient
outcome [16-21]. The biomarkers studied displayed dif-
ferent frequencies and patterns of expression; conse-
Table 3: Whole tissue section intra-reader agreement and agreement between the second whole tissue section and TMA
B7-H1 B7-H3 Survivin Ki-67 CAIX* IMP3
Kappa CCC CCC CCC CCC CCC
Whole section 0.78 0.97 0.71 0.90 0.94 0.96
Cores
1 0.21 (0.00 - 0.65) 0.80 (0.73 - 0.87) 0.35 (0.06 - 0.55) 0.63 (0.44 - 0.82) 0.85 (0.73 - 0.94) 0.73 (0.02 - 0.87)
2 0.21 (0.00 - 0.65) 0.81 (0.74 - 0.87) 0.40 (0.12 - 0.57) 0.72 (0.49 - 0.84) 0.82 (0.73 - 0.92) 0.79 (0.20 - 0.85)
3 0.38 (0.00 - 0.65) 0.83 (0.76 - 0.86) 0.43 (0.24 - 0.62) 0.76 (0.62 - 0.86) 0.80 (0.72 - 0.89) 0.81 (0.49 - 0.85)
4 0.38 (0.00 - 0.65) 0.83 (0.77 - 0.85) 0.44 (0.33 - 0.58) 0.79 (0.64 - 0.85) 0.78 (0.71 - 0.87) 0.82 (0.61 - 0.85)
5 0.52 (0.00 - 0.65) 0.83 (0.80 - 0.85) 0.45 (0.36 - 0.57) 0.81 (0.71 - 0.86) 0.77 (0.72 - 0.84) 0.82 (0.77 - 0.85)
6 0.52 (0.00 - 0.65) 0.84 (0.81 - 0.84) 0.45 (0.37 - 0.57) 0.81 (0.71 - 0.85) 0.76 (0.71 - 0.82) 0.82 (0.77 - 0.85)
7 0.65 (0.00 - 0.65) 0.84 (0.81 - 0.84) 0.46 (0.40 - 0.52) 0.82 (0.73 - 0.85) 0.75 (0.72 - 0.82) 0.82 (0.77 - 0.85)
8 0.65 (0.38 - 0.65) 0.84 (0.83 - 0.84) 0.46 (0.41 - 0.51) 0.82 (0.76 - 0.84) 0.74 (0.72 - 0.81) 0.82 (0.79 - 0.85)
9 0.65 (0.52 - 0.65) 0.84 (0.83 - 0.84) 0.46 (0.43 - 0.48) 0.82 (0.79 - 0.84) 0.73 (0.72 - 0.79) 0.82 (0.80 - 0.84)
10 0.65 (0.65 - 0.65) 0.84 (0.84 - 0.84) 0.46 (0.46 - 0.46) 0.82 (0.82 - 0.82) 0.73 (0.73 - 0.73) 0.82 (0.82 - 0.82)
*CAIX was analyzed using the minimum value across cores. All other biomarkers were analyzed using the maximum value across cores.
The kappa statistic is reported for B7-H1, whereas the concordance correlation coefficient (CCC) is reported for B7-H3, survivin, Ki-67, CAIX, and 
IMP3; the median (minimum, maximum) statistic from the 500 bootstrap samples is provided.
Table 4: Associations of whole tissue section quantification with RCC-specific death
Second Whole Section Quantification Wald χ2 Hazard Ratio (95% CI) P-value
B7-H1 (positive versus negative) 7.7 4.09 (1.51 - 11.08) 0.006
B7-H3 (increase of 5%) 11.7 1.14 (1.06 - 1.24) < 0.001
Survivin (increase of 5-cell per mm2) 31.3 1.32 (1.20 - 1.46) < 0.001
Ki-67 (increase of 5-cell per mm2) 30.2 1.07 (1.04 - 1.10) < 0.001
CAIX (decrease of 5%) 0.1 1.01 (0.92 - 1.10) 0.863
IMP3 (increase of 5%) 24.9 1.31 (1.18 - 1.45) < 0.001Eckel-Passow et al. Diagnostic Pathology 2010, 5:48
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quently, the number of TMA cores necessary to
adequately represent whole tissue sections was not the
same for all biomarkers. In particular, using a simulated
TMA, we determined that 2-to-3 cores appeared ade-
quate for Ki-67, IMP3, B7-H3, and CAIX, but even as
many as 10 cores resulted in poor agreement for B7-H1
and survivin with their whole tissue section counterparts.
This demonstrates that the number of TMA cores neces-
sary to represent whole tissue specimens is biomarker-
specific and thus a single TMA is not always appropriate
for a set of markers.
The second objective of this study was to evaluate the
ability of a TMA to discover associations between bio-
marker expression and patient outcome. For most of the
biomarkers studied, 2-to-4 cores appeared adequate to
identify the associations between expression and out-
come observed with whole tissue sections. However,
while whole tissue section B7-H1 was significantly associ-
ated with RCC-specific death, no significant associations
with patient outcome were detected using as many as 10
cores for this focal and rarely expressed biomarker, dem-
onstrating that a TMA may not be an appropriate tool for
some biomarkers. The suitability of TMA analysis of B7-
H1 for other studies and tumor types need to be further
evaluated. It is important to identify biomarkers that are
not well suited for TMA analysis in order to eliminate
false-negative conclusions obtained from TMA analyses.
Likewise, the sample size necessary to detect associations
is not equivalent for all biomarkers as a result of the vary-
ing expression patterns across biomarkers.
TMAs are commonly used to test various biomarkers
for their ability to predict disease outcome or response to
therapy since TMAs allow investigators to study many
tissue specimens using a uniform experimental process,
while simultaneously preserving limited tissue resources
[24]. As the results of the current study demonstrate, the
Figure 2 Box plots illustrating Wald chi-square statistics from 500 bootstrap samples. Testing associations of (A) B7-H3, (B) survivin, (C) Ki-67, 
(D) CAIX, (E) IMP3, and (F) B7-H1 expression with RCC-specific death using 1 and up to 10 cores. The lower, middle, and upper horizontal lines that 
comprise the boxes denote the 25th percentile, median, and 75th percentile of the distribution of test statistics from the 500 bootstrap samples. Using 
a significance level of 0.05, the critical value for a 1 degree-of-freedom chi-square test statistic is approximately 3.8. B7-H1 was modeled as dichoto-
mous (positive versus negative), whereas B7-H3, survivin, Ki-67, CAIX, and IMP3 were modeled as continuous.Eckel-Passow et al. Diagnostic Pathology 2010, 5:48
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general guideline that 3-to-4 cores are sufficient to ade-
quately represent whole tissue specimens does not hold
true for all biomarkers, and presumably for all malignan-
cies. Our results corroborate the conclusions of Fons et
al. [5] who suggested that the concordance between TMA
and whole tissue section quantification depends on the
expression pattern of the biomarker. Biomarkers with
focal and rare expression may not be well suited for TMA
analysis, as Linderoth et al. [25] demonstrated for BCL6
expression in diffuse large B-cell lymphoma, whereas bio-
markers with diffuse expression may be adequately repre-
sented by a limited number of TMA cores. Although it
may be concluded that TMAs are being successfully used
since they are uncovering significant associations
between biomarker expression and outcome, we high-
light the likelihood of obtaining false-negative findings
when using a single TMA to quantify multiple biomark-
ers with heterogeneous patterns of expression.
One limitation of our study is that we did not fully eval-
uate potential sources of variability in biomarker expres-
sion due to non-informative cores and core location.
However , as shown in T able 5, we did observe that the
outer ring of cores on the simulated TMA were more
likely to contain primarily normal, stromal, artifact,
necrotic, degenerative tissue or no tissue at all in compar-
ison to the inner ring of cores. The non-informative cores
were retained throughout the analyses, reasoning that
they represented missing cores on a real TMA (i.e., cores
that are lost during processing or that contained minimal
tumor). For example, Fons et al. [5] reported that 10%,
8%, and 9% of TMA cores were not assessable for their
study of oestrogen and progesterone receptor, p53, and
epithelial membrane antigen, respectively. Similarly, Gil-
lett et al. [26] reported that 12% and 13% of TMA cores
had floated off during the immunohistochemical tech-
nique and 10% and 12% of the stained sections did not
contain invasive tumor when evaluating estrogen and
progesterone receptors, respectively. Thus, the number of
non-informative cores observed with our simulated TMA
is similar to what others have observed using real TMAs.
Additionally, using the simulated TMA, we were unable
to evaluate variability in biomarker expression associated
with core size or different slices of the TMA block. With
respect to core size, Lesnikova et al. [24] evaluated cervi-
cal neoplasia specimens and concluded that 1 mm tissue
cores were more appropriate than 0.6 or 2 mm cores and
provide a suitable compromise of being large enough to
be representative yet small enough to be high through-
put. With respect to evaluating different slices of the
TMA block, Hager et al. [4] evaluated RCC specimens
and concluded that the percentage of lost or non-infor-
mative cores tripled from the first slice to the last slice of
the TMA block primarily due to the presence of limited
(> 25%) tumor tissue, core folding, and necrotic tissue.
Lastly, the use of a TMA template mask placed on previ-
ously stained whole tissue sections did not allow us to
address additional variability that can be introduced by
day-to-day fluctuations in staining procedures or TMA
core edge effects.
While non-informative cores, core location, core size,
repeated sectioning of the TMA block, and staining fluc-
tuations certainly contribute to variability in biomarker
expression, variability may also arise by the use of a single
TMA to study multiple biomarkers without an under-
standing of their varied expression patterns in whole tis-
sue sections. This often underestimated variability may
contribute to the inability of promising biomarkers to
achieve clinical utility. As McShane et al. [27] remarked,
while numerous biomarkers have been studied, the num-
ber of biomarkers that have attained clinical utility is
"pitifully small". Initial reports of a biomarker's promising
ability to predict a clinical outcome are rarely substanti-
ated by subsequent studies of the same biomarker or
related biomarkers. McShane and colleagues cite a num-
ber of reasons for these inconsistent findings including
insufficient sample size, inappropriate statistical meth-
ods, and use of biomarker assays that are not standard-
ized and reproducible. Herein, we demonstrate that
studies that employ TMA technology without first evalu-
ating agreement in biomarker expression with whole tis-
sue sections may further contribute to washout of
biomarker utility in the clinical setting.
In summary, TMAs are useful for studying a given bio-
marker provided that the number of TMA cores neces-
sary to accurately represent whole tissue section
biomarker expression is established on a biomarker-spe-
cific and tumor-specific basis as there is not a one-size-
fits-all TMA. We recommend that guidelines for evaluat-
ing the appropriateness of a TMA for a given biomarker
Table 5: Number of non-informative cores observed (out of 
100 patients) on the simulated TMA
Core B7-H1 B7-H3 Survivin Ki-67 CAIX IMP3
15 7 5 4 1 3 1 5
23 7 8 49 1 6
34 7 7 7 1 7 2 0
46 6 1 41 0 2 1 1 3
5 5 8 13 6 15 12
66 7 9 9 1 2 1 5
75 5 1 01 1 2 8 1 3
84 4 1 1 7 2 0 8
94 2 6 378
10 3 7 3 3 9 13
Cores 1, 2, 9, and 10 denote the inner ring and cores 3-8 denote the 
outer ring of the simulated TMA (Figure 1B).Eckel-Passow et al. Diagnostic Pathology 2010, 5:48
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and tumor type should be developed, similar to the
REMARK guidelines established for prognostic studies
[27]. We further recommend that any claims suggesting
that a TMA can be used to represent biomarker expres-
sion in whole tissue sections be supported by published
data that disclose rigorous evidence of these validation
steps.
Additional material
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